Seres Therapeutics, Inc. (MCRB - Free Report) was a big mover last session, as the company saw its shares rise a little above 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $10.73 to $12.46 in the past one-month time frame.
The company has seen one positive estimate revision in the past 30 days. Also, its Zacks Consensus Estimate moved higher over the same timeframe. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Seres Therapeutics currently holds a Zacks Rank #2 (Buy), while its Earnings ESP is negative.
Seres Therapeutics, Inc. Price
Another top-ranked stock in the Medical - Biomedical and Genetics industry is Vertex Pharmaceuticals Incorporated (VRTX - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is MCRB going up? Or down? Predict to see what others think: Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Seres Therapeutics, Inc. (MCRB - Free Report) was a big mover last session, as the company saw its shares rise a little above 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $10.73 to $12.46 in the past one-month time frame.
The company has seen one positive estimate revision in the past 30 days. Also, its Zacks Consensus Estimate moved higher over the same timeframe. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Seres Therapeutics currently holds a Zacks Rank #2 (Buy), while its Earnings ESP is negative.
Seres Therapeutics, Inc. Price
Another top-ranked stock in the Medical - Biomedical and Genetics industry is Vertex Pharmaceuticals Incorporated (VRTX - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is MCRB going up? Or down? Predict to see what others think: Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on VRTX - FREE
Get the latest research report on MCRB - FREE